Please use this identifier to cite or link to this item:
https://hdl.handle.net/10316/101628
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Gravito-Soares, Marta | - |
dc.contributor.author | Gravito-Soares, Elisa | - |
dc.contributor.author | Gomes, Dário | - |
dc.contributor.author | Tomé, Luís | - |
dc.date.accessioned | 2022-09-05T10:18:05Z | - |
dc.date.available | 2022-09-05T10:18:05Z | - |
dc.date.issued | 2019 | - |
dc.identifier.issn | 1665-2681 | pt |
dc.identifier.uri | https://hdl.handle.net/10316/101628 | - |
dc.description.abstract | Introduction and aim. The association between lysosomal acid lipase (LAL) activity and liver steatosis or fibrosis is poorly st ud- ied. The aim of our study was to determine the predictive power of LAL for cryptogenic liver steatosis and cryptogenic significant fi- brosis/cirrhosis. Material and methods.Material and methods.Material and methods.Material and methods.Material and methods. Cross-sectional observational study of 101 adult patients with unexplained elevated liver enzymes/hepatomegaly with or without dyslipidemia submitted to the determination of LAL activity and LIPA gene (E8SJM- C.894GoA) mutation. Seventy-one patients underwent liver biopsy or FibroScan®. Patients with an identifiable liver dysfunction cause and well-stablished NAFLD/NASH risk factors were excluded. Predictors for liver steatosis, significant fibrosis (t F2) or cir- rhosis (F4) were evaluated. Results.Results.Results.Results.Results. Liver steatosis and fibrosis were mainly assessed by liver biopsy (74.6%; n = 53). Steatosis was present in 62.0% (n = 44), significant fibrosis in 47.9% (n = 34) and cirrhosis in 39.4% (n = 28). The median LAL was 0.36 (0.21-0.46)nmol/spot/h (vs. 0.29 (0.20-0.47); p = 0.558) for liver steatosis, 0.22 (0.11-0.29) nmol/spot/h (vs. 0.40 (0.34-0.51); p < 0.001) for significant fibrosis and 0.21 (0.11-0.27) nmol/spot/h (vs. 0.40 (0.32-0.52); p < 0.001) for cirrhosis. No LIPA gene mutations were found. LAL activity was the strongest predictor of significant fibrosis (AUROC: 0.833; p < 0.001) with a cut-off of 0.265(sensi- tivity: 85.9%; specificity: 75.0%) and cirrhosis (AUROC: 0.859; p < 0.001) with a cut-off of 0.235 (sensitivity: 86.2%; specifi city: 75.0%), being higher than FIB4, GUCI or APRI. However, LAL activity was not associated with liver steatosis (AUROC: 0.536; p = 0.558). Conclusion.Conclusion.Conclusion.Conclusion.Conclusion. LAL activity can be considered a non-invasive new marker of cryptogenic liver fibrosis with higher accuracy than other known biomarkers. LAL activity < 0.265 nmol/spot/h was strongly associated with cryptogenic significant fibrosis and < 0.235 nmol/spot/h with cryptogenic cirrhosis. LAL activity was not associated with cryptogenic liver steatosis | pt |
dc.language.iso | eng | pt |
dc.rights | openAccess | pt |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | pt |
dc.subject | LAL | pt |
dc.subject | Chronic liver disease | pt |
dc.subject | Fibrosis degree | pt |
dc.subject | E8SJM mutation | pt |
dc.subject | Serum biomarkers | pt |
dc.subject.mesh | Biomarkers | pt |
dc.subject.mesh | Biopsy | pt |
dc.subject.mesh | Cross-Sectional Studies | pt |
dc.subject.mesh | Elasticity Imaging Techniques | pt |
dc.subject.mesh | Female | pt |
dc.subject.mesh | Follow-Up Studies | pt |
dc.subject.mesh | Humans | pt |
dc.subject.mesh | Liver | pt |
dc.subject.mesh | Liver Cirrhosis | pt |
dc.subject.mesh | Male | pt |
dc.subject.mesh | Middle Aged | pt |
dc.subject.mesh | Prognosis | pt |
dc.subject.mesh | Retrospective Studies | pt |
dc.subject.mesh | Risk Factors | pt |
dc.subject.mesh | Sterol Esterase | pt |
dc.title | Lysosomal Acid Lipase: Can it be a New Non-Invasive Serum Biomarker of Cryptogenic Liver Fibrosis and Cirrhosis? | pt |
dc.type | article | - |
degois.publication.firstPage | 78 | pt |
degois.publication.lastPage | 88 | pt |
degois.publication.issue | 1 | pt |
degois.publication.title | Annals of Hepatology | pt |
dc.peerreviewed | yes | pt |
dc.identifier.doi | 10.5604/01.3001.0012.7865 | pt |
degois.publication.volume | 18 | pt |
dc.date.embargo | 2019-01-01 | * |
uc.date.periodoEmbargo | 0 | pt |
item.fulltext | Com Texto completo | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.languageiso639-1 | en | - |
item.openairetype | article | - |
item.cerifentitytype | Publications | - |
item.grantfulltext | open | - |
crisitem.author.orcid | 0000-0002-0635-2475 | - |
crisitem.author.orcid | 0000-0002-5220-8757 | - |
Appears in Collections: | FMUC Medicina - Artigos em Revistas Internacionais |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
1-s2.0-S1665268119303096-main.pdf | 307.39 kB | Adobe PDF | View/Open |
SCOPUSTM
Citations
5
checked on Nov 17, 2022
WEB OF SCIENCETM
Citations
5
checked on May 2, 2023
Page view(s)
104
checked on Oct 16, 2024
Download(s)
55
checked on Oct 16, 2024
Google ScholarTM
Check
Altmetric
Altmetric
This item is licensed under a Creative Commons License